Metabolon Logo
Metabolon Logo

Metabolon is pleased to exhibit at Biomarkers 2024 in London, England. As Europe’s flagship event for biomarker research, this conference is designed to unveil the forefront of biomarker trends and tools. This event assembles top experts from global pharmaceutical organizations, groundbreaking biotech companies, and esteemed academic institutions, all engaged in diverse therapeutic areas and stages of drug development.

Join our team at Booth 4 and on February 29th, where we will give a presentation during the Track 2 session on ‘Biomarkers for Diagnostics & Precision Medicine’ at 2:30 pm.

Date: 2/29/2024 – 3/1/2024

Location: London, UK

More information:

Booth No. 4

Oral Presentation

Advancing Drug Development with Metabolomics: Integrating Small Molecule Biomarkers in Clinical Trials 

Track: New & Emerging Biomarker Technologies & Biomarker Data Analytics  
Date: Friday, March 1, 2024, 10:30 AM 
Location: Conference Room 2 



Dr. Natasa Giallourou

Dr. Natasa Giallourou is a Field Metabolomics Scientist supporting Metabolon’s International Business activities. She provides scientific counsel for metabolomics applications in the biopharma and academic sectors. Natasa obtained her PhD in Metabolomics from the University of Reading and holds an MSc in Nutrition and Health from Wageningen University and a BSc in Biology from the University of Leeds.

Prior to joining Metabolon, Natasa served as a Marie Skłodowska-Curie Postdoctoral Fellow at Her research projects involved integrating metabolomic data with other 'omics' data in population-based studies, with a focus on identifying biomarkers for complex diseases. She has also worked as a Postdoctoral Research Associate at Imperial College London, where she specialized in utilizing metabolic phenotyping to address global health challenges, particularly in the field of public health nutrition.

Natasa sits on the Board of Directors of the International Metabolomics Society and is also an advisor to the Early-career Member’s Network for young metabolomics scientists.

Presentation Details

Advancements in drug development through the integration of metabolomics are revolutionizing clinical trials by utilizing small molecule biomarkers. This approach enhances understanding of drug MoA, safety profiles, and efficacy. The presentation will focus on Metabolon’s approach to biomarker discovery for drug development, with application examples highlighting its critical role in advancing and refining therapeutic interventions.

Panel Discussion 

Reflection When Biomarker Development Fails And Lessons Learnt In Pre-Clinical Development 

Date: Thursday, February 29, 2024, 11:30 AM 
Location: Conference Room 2